MedTrace Logo

Efficacy of Rupatadine 5, 10 and 20 mg in Chronic Idiopathic Urticaria

NCT00199238 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 248

Last updated 2022-02-18

No results posted yet for this study

Summary

The objective of this study is to evaluate the efficacy and safety of rupatadine for the treatment of CIU symptoms.To assess the clinical efficacy of a dose ranging of rupatadine fumarate (5mg, 10mg, and 20 mg) compared with placebo for relief of CIU symptoms.

Conditions

  • URTICARIA

Interventions

DRUG

Rupatadine Fumarate

Sponsors & Collaborators

  • J. Uriach and Company

    lead INDUSTRY

Principal Investigators

  • EVA Arnaiz, PhD · J. Uriach y Compañía

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-10-28
Primary Completion
2003-11-25
Completion
2004-09-27

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00199238 on ClinicalTrials.gov